It has been well established that the frequencies of genomic variants can vary greatly between the populations of different countries. We sought to quantify the intra-population variability in Ghana to determine the value of genotyping studies done at a nationwide level. Further, we investigated the differences between the Ghanaian and other African populations to determine the quality of genomic representation provided by a small subgroup within the continent with regard to the general population. We genotyped 934 unrelated Ghanaian individuals for 15 single nucleotide polymorphisms (SNPs) from genes defined as clinically relevant based on their reported roles in the transport of, metabolism of, or as targets of the medicines listed in the World Health Organization Essential Medicines list. Populations within Ghana and between nations in Western Africa were genetically cohesive. In contrast, populations in other areas of Africa were genetically divergent. Gene allele frequency also differed significantly between the populations in African nations and the United States for several of the SNPs. These results demonstrate that national populations in similar geographic regions, like Africa, may have widely varying genetic allele frequencies for clinically relevant SNPs. Further genotyping studies of specific populations are necessary to provide the best medical care to all individuals.
Introduction
Many areas of the world are under-represented in current pharmacogenetics research, 1,2 despite clear evidence that demonstrates that many clinically relevant DNA polymorphisms have significantly variable allele frequencies among different world populations. [3] [4] [5] [6] In particular, there is a paucity of pharmacogenetic information in African countries. Initiatives such as the International HapMap project (http://www.hapmap.org) have included samples from Yoruban individuals (30 trios) to represent African genomics, although realizing that 90 individuals will not represent the entire African population. 7 Data suggest that even within ethnic groups, allele frequencies can differ considerably. For example, significant differences are found for GSTT1*0 (null) allele frequencies (0.13-0.28) between populations defined as Caucasian. 8 Similarly, there is evidence that allele frequencies between African populations can also differ significantly. The Gambia, in Western Africa, has one of the highest recorded allele frequencies for GSTP1 I105V (0.53), whereas South Africa has one of the lowest (0.14). 9, 10 These data are consistent with recent reports that global measures of genetic diversity are greater between African individuals than between Africans and Eurasians. 11, 12 Genetic variation, such as single nucleotide polymorphisms (SNPs), plays an important role clinically. SNPs have been shown to alter enzyme activity, resulting in abnormally increased or decreased metabolism of drugs. For instance, VKORC1 -1639 G4A (rs9923231), located in the promoter region of vitamin K epoxide reductase, has been shown to diminish enzyme activity, causing a 'low dose' phenotype in response to treatment with the blood thinning agent warfarin. Patients carrying the 'A' allele require significantly lower dosages of warfarin to reach therapeutic anticoagulation, while avoiding severe adverse side effects. 13 The 'A' allele has been reported to occur more frequently in East Asian populations-0.91 and 0.94 in Chinese and Japanese cohorts, respectively-than in the Caucasian population (0.38).
14,15 Accordingly, the US FDA has included such genetic information in the warfarin prescribing information, as an aid to achieving therapeutic doses in a more rapid and safe manner. Similar recommendations have been made for mercaptopurine, azathioprine, codeine, carbamazepine, and irinotecan (http://www.fda. gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ ucm083378.htm).
Ideally, to optimize therapeutic outcomes, all patients would be genotyped for relevant genetic variants before beginning a drug treatment regimen. Unfortunately, this remains unfeasible, in part due to financial constraints. As an alternative, population allele frequency data may be able to substitute for individual genotyping. However, the scarcity of data from African countries leaves these populations at a distinct disadvantage for receiving the potential benefits of genetically tailored therapy.
To address the lack of data on allele frequency of clinically relevant SNPs within African populations, we genotyped 934 individuals from Ghana, in Western Africa. Genes were defined as clinically relevant based on their reported roles in the transport of, metabolism of, or as targets of the 80 medicines listed on the 15th World Health Organization (WHO) Essential Medicines list. 16 SNPs were selected from those genes based on their known effect on the function of the protein product (Table 1) .
We compared the allele frequencies for five Ghanaian tribes with the largest numbers of self-identified members in the study to determine the intra-country genetic variation. Further, we compared the allele frequencies for the Ghanaian population, as a whole, with earlier reported frequencies for other African nations and the allele frequencies from Yoruba individuals in the HapMap database to estimate intra-continental, inter-country variation. Additionally, we compared the Ghanaian population with the published genotypes for populations in the United States. Many existing US studies were performed using primarily Caucasian subjects (ABCG2 Q141K, CYP3A5*3C, DPYD*2A GSTP1 I105V, NAT2*6, TPMT 719A4G, TYMS 1494del). [17] [18] [19] [20] Some studies included allele frequencies from different ethnicities such as European-Americans, African-Americans, AsianAmericans, and Hispanic-Americans (ABCB1 3435C4T, CYP2C19*2, CYP2C9*2 and *3, CYP3A4*1B, and UGT1A1 -3156G4A).
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Results
All of the genotypes were found to be in Hardy-Weinberg equilibrium. From the 934 total samples, between 787 and 919 genotypes were available for each SNP. The genotype results are presented in Table 2 . Many of the SNPs had not been examined in the Ghanaian population before this study. For those SNPs that had been genotyped earlier in Ghanaians (ABCB1 3435C4T and CYP3A4*1B), 18 our allele frequencies were similar to those reported in the literature (Table 3) .
Intra-population analysis between Ghanaian tribes
We analyzed intra-population variations within Ghana. The tribes with the largest self-reported membership (Akwapim, Ashanti, Ewe, Fanti, and Ga) were analyzed separately to determine if the five subpopulations were genetically distinct ( Table 4 ). The only significant genetic difference Metabolism RT-inhibitors (HIV), anti-cancer, anti-leprosy, NSAIDs/anti-migraine detected between the tribes was CYP3A4*1B (Po0.008), which failed to meet significance once the Bonferroni Correction was applied (Table 5) .
Inter-population analysis between African populations
Although large-scale genotyping of most African populations has not been undertaken, we compared the genotype frequencies obtained from the Ghanaian population in our study with available reports for other African populations ( Table 3 ). The Ghanaian cohort was found to be most similar to other West African populations. Guinea-Bisseau, Nigeria, and Senegal reported SNP frequencies of 0.81, 0.87, and 0.78, respectively, for CYP3A4*1B, similar to the frequency of 0.78 in the Ghanaian cohort. 18 Likewise, the reported frequencies of GSTP1 I105 V from Cameroon (0.46) and The Gambia (0.53) were similar to that found in Ghana (0.50). 18 Benin, Burkina Faso, and Gabon also reported allele frequencies similar to those found in Ghana for other individual SNPs. 18, 22, 23 Of note, however, is the wide range of frequency variation in CYP3A5*3C, with Senegal reporting a frequency of 0.31 and Nigeria at 0.06.
18 Ghana (0.14) and the Gambia (0.21) were found to fall within this range. 18 Interestingly, although the frequencies for some SNPs from non-West African nations were similar to those in the Ghanaian population (CYP2C19*2, NAT2*6), many others were found to diverge significantly from those in Ghana, particularly in countries with strong ties to other geographic and cultural regions, such as Egypt. 18, [24] [25] [26] [27] In fact, for many of the SNPs, the Egyptian population was more similar to United States populations than to our Ghanaian cohort or other African countries (ABCB1 3435C4T, CYP2C19*2, CYP2C9*2/*3, GSTP1 I105 V, TPMT 719A4G; Table 3 ). 18 Other African nations differed from Ghana significantly for individual SNPs. For example, the frequencies of GSTP1 I105 V reported in Tanzania (0.16), South Africa (0.14), Zimbabwe (0.24), and Tunisia (0.34) were significantly lower than in Ghana (0.50). 18 As noted earlier, CYP3A5*3C demonstrated the greatest variability in frequency across different populations, ranging from 0.84 in Algeria to 0.07 in Namibia and the Democratic Republic of the Congo. 18 Comparison of Ghanaian population to Yoruba HapMap data The International HapMap Project provides SNP genotype data for millions of SNPs from four populations representing East Asian, African, and Caucasian groups. Thirty family trios (mother, father, child) from the Yoruba people of Nigeria were chosen to represent Africa. 28 We compared the results from the Ghanaian population in our study with those of the Yoruba individuals in the HapMap (Table 3) . We found that although some of the P-values when comparing Ghana and the Yoruba allele frequencies were less than 0.05 (GSTP1 I105 V P ¼ 0.01; NAT2 *6 P ¼ 0.03), they all failed to reach significance when the Bonferroni Correction was applied. Like the Ghanaians, the Yoruba were most similar to other West African populations but differed significantly from other African populations and the United States. Table 2 Genotypes and allele frequencies of pharmacogenetically relevant polymorphisms observed in the Ghanaian population (% in parenthesis)
Total # genotyped (26) 7 (1) 69 (8) 3 (0.3) 6 (1) 187 (23) 
Comparison of Ghanaian and US populations
We also compared the genotyping results from Ghana with the allele frequencies reported for the US Caucasians (Table 3 ) because much of the population frequency data in the published literature is from the United States, and it plays a major role in drug development. In comparison to the United States, the allele frequencies in Ghana were significantly different for many of the SNPs, particularly ABCB1 3435C4T, ABCG2 Q141 K, CYP3A4*1B and CY-P3A5*3C, for which the major and minor alleles were reversed in the two populations ( Figure 1 ).
17,18
Discussion
This study assessed SNPs from genes involved in the biological activity of (transport, metabolism, or targeted by) 80 of the drugs listed on the WHO Essential Medicines list. We found that the allelic frequencies in the Ghanaian population are generally similar to other West African countries, but differ significantly from other African populations. These results indicate that genotype data from one group or subgroup (i.e., nation or ethnicity) should not be overly generalized and applied to genetically distinct groups (i.e., other nations or ethnicities). Furthermore, the 90 Yoruba individuals selected to represent the African populations on the HapMap, do not adequately account for the vast genetic variability present in different African countries. In contrast, however, we detected a considerable degree of genetic homogeneity within the Ghanaian population. Although it is indeed true that great variation across the human genome occurs in African populations, this is not observed when the focus is on a small number of causative SNPs. This suggests that genotyping studies within a country may be applied to other regions of the country, provided that subgroups known to be genetically isolated are not included. In addition, we compared the Ghanaian population with that of the United States. The genotyping data we used for comparison from the United States was primarily composed of Caucasians, as drug efficacy and dosing studies are frequently performed in the United States, Canada, or Europe, where the populations are primarily Caucasians. The results from this study strongly suggest that Ghanaian, Table 5 Allele frequencies of pharmacogenetically relevant polymorphisms in five Ghanaian tribes Minor allele Although the allele frequencies within Ghana were consistent between self-reported tribes, this study only compared the five tribes with representing the largest portion of our cohort. Variability between other regions or tribes within Ghana may be present and may not be accounted for in this study.
It is widely acknowledged that using genotype data from the national population is a poor surrogate for individual genotyping, even where genetic homogeneity exists. This study confirms that using one country to estimate the allele frequency of a larger region is insufficient, particularly for African populations, which have been shown to exhibit high genetic diversity. Our data further suggests that if individual genotype data are not available, it would be unwise to extrapolate an individual's genotype based on genetic data from beyond the national population. Although Ghana and West Africa displayed considerable genetic homogeneity, other regions of Africa diverged intraregionally. However, using national genetic data as a substitute for individual genotyping is currently the most practicable option, due to financial and technological limitations. Thus, for the foreseeable future, knowledge of allele frequencies within each country is essential, if an individual is to receive genetically tailored drug therapy. Unfortunately, there is currently minimal genotype data for most African countries, which will continue to exclude most African individuals from genetically based healthcare recommendations.
In conclusion, our study confirmed that great genomic diversity exists among different national populations. By focusing on SNPs known to be associated with drug processing and/or targeting, we were able to directly assess the advisability of applying genotype data or drug tolerance and efficacy guidelines to groups other than the tested population. We determined that caution should be exercised when making generalized treatment recommendations for other population subgroups. In the absence of worldwide individual genomic sequencing, genotyping of a greater variety of national groups must be carried out, so that treatment guidelines can be customized at least at a national level. Thus, we can begin to learn how to provide the best medical care for populations around the world.
Materials and methods
Population samples
Genomic DNA from 934 healthy unrelated Ghanaian volunteers (535 male, 399 female, median age 24) was extracted as described earlier. 4 The most common selfreported tribes are listed in Table 4 . This study was approved by the Washington University Human Studies Committee and the Ethics Committee of the University of Ghana.
Genotyping
Genotypes for ABCB1 3435C4T, ABCG2 Q141 K, CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP3A4*1B, CYP3A5*3C, DPYD*2A, GSTP1 I105 V, NAT2*6, NAT2*14, TNFa -238G4A, TPMT 719A4G, TYMS 1494del, and UGT1A1 -3156G4A were determined using PCR and Pyrosequencing methodology as described earlier (assay details available on request). 29 The major allele was defined by the allele frequency in the United States, as reported on www.pgeni.org for ABCB1 3435C4T, CYP2C19*2, CYP2C9*2 and *3, CYP3A4*1B, CYP3A5*3C, DPYD*2A, GSTP1 I105V, and TPMT 719A4G. For the remaining SNPs, the major allele was defined as the most commonly occurring allele in the Ghanaian population cohort. Actual genotype numbers varied (787-919) depending on DNA availability. Genotype data for a subset of 206 samples for ABCB1 3435C4T and 217 samples for TPMT 719A4G has been described earlier. 4, 5 Analysis Hardy-Weinberg equilibrium was assessed using HWSIM (http://krunch.med.yale.edu/hwsim/) with 10 000 iterations. Significant differences between allele frequencies for all Ghanaian individuals versus earlier published Figure 1 Comparison of the variant allele frequencies of (a) ABCB1 3435C4T and (b) CYP3A4*1B from this study versus earlier published frequencies from Ghana 18 , other African populations 18 , and Caucasian Americans (US) 18 .
frequencies from other world populations, and between Ghanaian self-reported tribes with 450 individuals (Akwapim, Ashanti, Ewe, Fanti, and Ga; Table 4) were assessed with w 2 analysis using Stata Data Analysis and Statistical software. The Bonferroni Correction was applied to determine the P-value threshold of significance: 0.05/ n ¼ 7.0 Â 10 À4 (n ¼ 71). 
